A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
Status:
Completed
Trial end date:
2017-02-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad,an increased dose of
Abiraterone Acetate in combination with prednisone has on patients and their prostate cancer.
This study will investigate whether an increased-dose (2,000mg daily) is safe and potentially
effective when given to patients whose cancer has grown while taking the standard dose.